Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Pharmala Biotech Holdings Inc C.MDMA

Alternate Symbol(s):  MDXXF

PharmAla Biotech Holdings Inc. is a Canada-based biotechnology company. The Company is focused on the development, manufacture and sales of methylenedioxy methamphetamine (MDMA) and methylenedioxy phenethylamines (MDXX) class molecules in service to the burgeoning clinical research community and growing commercial use cases in select jurisdictions. The Company has three primary business lines... see more

CSE:MDMA - Post Discussion

View:
Post by inviolablspirit on Jun 06, 2024 10:31am

Looking ahead

As mentioned by Nick, his focus is places outside the US, so Pharmala will continue to truck ahead.  Nothing has really changed for them. There are many drugs that are approved In Europe and Canada that are not approved in the US.  As Nick pointed out in his last interview the cost to do business in the US is about $100 million or more for clinical trials.   So his focus has always been other countries.  And other countries will moving to do their own clinical studies which is where Pharmala comes in as a possible supplier or partner.
Comment by inviolablspirit on Jun 06, 2024 11:12am
My expectation would be is that Nick and his team are out there secuing deals for more clincial trials in other countries. ...and looking for a partner for clinical testing of their MDMA variants (ex. ALA-002).
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities